Press coverage about Abeona Therapeutics (NASDAQ:ABEO) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Abeona Therapeutics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.8014780091578 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Swinging Stocks: Endo International plc (NASDAQ:ENDP), The Home Depot, Inc. (NYSE:HD), Abeona Therapeutics Inc … (thestreetpoint.com)
- 50 days simple moving average (SMA50) in the Limelight: Abeona Therapeutics Inc. (NASDAQ:ABEO), PolyMet Mining … (stocksnewspoint.com)
- Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. – ABEO (finance.yahoo.com)
- Gene Therapy for Mucopolysaccharidosis Pipeline Analysis Report 2018 Featuring Sangamo Therapeutics, Swedish Orphan Biovitrum & uniQure (markets.businessinsider.com)
- Abeona Therapeutics Inc (ABEO) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
ABEO has been the subject of a number of research reports. Maxim Group set a $35.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a research report on Monday, March 19th. Cantor Fitzgerald set a $36.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 20th. Zacks Investment Research cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 21st. HC Wainwright set a $30.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 2nd. Finally, ValuEngine raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Abeona Therapeutics has an average rating of “Buy” and an average target price of $28.56.
Shares of NASDAQ:ABEO traded down $0.80 on Thursday, reaching $15.75. The company had a trading volume of 13,835 shares, compared to its average volume of 945,965. Abeona Therapeutics has a twelve month low of $4.85 and a twelve month high of $22.75. The stock has a market capitalization of $761.61 million, a P/E ratio of -23.71 and a beta of 1.27.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Abeona Therapeutics had a negative return on equity of 23.57% and a negative net margin of 939.83%. The company had revenue of $2.60 million during the quarter, compared to analysts’ expectations of $0.27 million. equities analysts forecast that Abeona Therapeutics will post -0.7 earnings per share for the current fiscal year.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.